Epac activation with 8CPT-AM induced RLC phosphorylation in the perfused hearts. حسب Yoshiki Ohnuki (576298)

Epac activation increased RLC phosphorylation via PLC/PKC. حسب Yoshiki Ohnuki (576298)

SOSV loads in specimens obtained from bats in the SOSV-MARV experimental cohort. حسب Amy J. Schuh (8520354)

KASV loads in specimens obtained from bats in the KASV-MARV experimental cohort. حسب Amy J. Schuh (8520354)

Pre- and post-study virus-specific IgG responses for bats in the SOSV-MARV and KASV-MARV experimental cohorts. حسب Amy J. Schuh (8520354)

Image1_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF حسب Xiang Xiao (44417)

"…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …"

Image2_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF حسب Xiang Xiao (44417)

"…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …"

Image8_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF حسب Xiang Xiao (44417)

"…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …"

Image5_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF حسب Xiang Xiao (44417)

"…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …"

Image6_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF حسب Xiang Xiao (44417)

"…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …"

Image3_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF حسب Xiang Xiao (44417)

"…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …"

Image4_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF حسب Xiang Xiao (44417)

"…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …"

Image7_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF حسب Xiang Xiao (44417)

"…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …"

Damage characteristics of PU/WG layer. حسب Hao Yu (157186)

الموضوعات:

Joint Efficiency (%) of ABS Polymers at 800 rpm and 1200 rpm. حسب Shaheer Ahmed Khan (17797647)

الموضوعات:

Schematic of fixture. حسب Shaheer Ahmed Khan (17797647)

الموضوعات:

Average shore hardness values of ABS and PC welded samples. حسب Shaheer Ahmed Khan (17797647)

الموضوعات:

Fabricated Fixture with labelled view. حسب Shaheer Ahmed Khan (17797647)

الموضوعات:

Joint Efficiency (%) of PC Polymers at 800 rpm and 1200 rpm. حسب Shaheer Ahmed Khan (17797647)

الموضوعات:

Tensile Strength (MPa) of PC Polymers at 800 rpm and 1200 rpm. حسب Shaheer Ahmed Khan (17797647)

الموضوعات: